BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 32139603)

  • 1. Combined and sequential non-invasive approach to diagnosing non-alcoholic steatohepatitis in patients with non-alcoholic fatty liver disease and persistently normal alanine aminotransferase levels.
    Zheng KI; Liu WY; Pan XY; Ma HL; Zhu PW; Wu XX; Targher G; Byrne C; Wang XD; Chen YP; Lu F; Zheng MH
    BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32139603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis--a comparison with routine biochemical markers.
    Chan WK; Sthaneshwar P; Nik Mustapha NR; Mahadeva S
    PLoS One; 2014; 9(9):e105903. PubMed ID: 25184298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease.
    Gao F; Huang JF; Zheng KI; Pan XY; Ma HL; Liu WY; Byrne CD; Targher G; Li YY; Chen YP; Chan WK; Zheng MH
    J Gastroenterol Hepatol; 2020 Oct; 35(10):1804-1812. PubMed ID: 32246876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
    Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
    Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum cytokeratin-18 fragment levels as noninvasive marker of nonalcoholic steatohepatitis in the chilean population.
    Arab JP; Hernández-Rocha C; Morales C; Vargas JI; Solís N; Pizarro M; Robles C; Sandoval D; Ponthus S; Benítez C; Barrera F; Soza A; Riquelme A; Arrese M
    Gastroenterol Hepatol; 2017; 40(6):388-394. PubMed ID: 28359548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MACK-3 (combination of hoMa, Ast and CK18): A promising novel biomarker for fibrotic non-alcoholic steatohepatitis.
    Chuah KH; Wan Yusoff WNI; Sthaneshwar P; Nik Mustapha NR; Mahadeva S; Chan WK
    Liver Int; 2019 Jul; 39(7):1315-1324. PubMed ID: 30825254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Serum Biomarkers in Non-Invasive Diagnosis of Non-Alcoholic Steatohepatitis.
    Yang M; Xu D; Liu Y; Guo X; Li W; Guo C; Zhang H; Gao Y; Mao Y; Zhao J
    PLoS One; 2015; 10(6):e0131664. PubMed ID: 26121037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study.
    Zhang H; Rios RS; Boursier J; Anty R; Chan WK; George J; Yilmaz Y; Wong VW; Fan J; Dufour JF; Papatheodoridis G; Chen L; Schattenberg JM; Shi J; Xu L; Wong GL; Lange NF; Papatheodoridi M; Mi Y; Zhou Y; Byrne CD; Targher G; Feng G; Zheng M
    Chin Med J (Engl); 2023 Feb; 136(3):341-350. PubMed ID: 36848175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Aspartate Aminotranferase and Tumor Necrosis Factor-α as Non Invasive Diagnostic Tools for Non Alcoholic Steatohepatitis (NASH).
    Purnomo HD; Mundhofir FE; Kasno ; Sudijanto E; Darmono ; Daldiyono ; Djokomoeljanto R; Faradz SM
    Acta Med Indones; 2015 Jan; 47(1):16-23. PubMed ID: 25948763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical significance of serum Ck18-M65 and M30 levels in patients with chronic hepatitis B combined with nonalcoholic steatohepatitis and liver fibrosis.
    Dai L; Yan Y; Chen Q
    Medicine (Baltimore); 2024 Jun; 103(23):e38342. PubMed ID: 38847670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Validation Study of a Diagnostic Algorithm to Detect NASH and Fibrosis in NAFLD Patients With Low NAFLD Fibrosis Score or Liver Stiffness.
    Liebig S; Stoeckmann N; Geier A; Rau M; Schattenberg JM; Bahr MJ; Manns MP; Jaeckel E; Schulze-Osthoff K; Bantel H
    Clin Transl Gastroenterol; 2019 Aug; 10(8):e00066. PubMed ID: 31397685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of GP73 in the diagnosis of non-alcoholic steatohepatitis and the staging of hepatic fibrosis.
    Li Y; Yang Y; Li Y; Zhang P; Ge G; Jin J; Du T; Ma M; Na L; Ding L; Sheng H
    J Int Med Res; 2021 Nov; 49(11):3000605211055378. PubMed ID: 34772312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: biomarkers as diagnostic tools for liver damage assessment in adult patients from Argentina.
    Valva P; Rios D; Casciato P; Gadano A; Galdame O; Mullen E; Bertot G; de Matteo E; Preciado MV
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):637-644. PubMed ID: 29384795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Nonalcoholic Fatty Liver Disease Via a Novel Panel of Serum Adipokines.
    Jamali R; Arj A; Razavizade M; Aarabi MH
    Medicine (Baltimore); 2016 Feb; 95(5):e2630. PubMed ID: 26844476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between serum cytokeratin-18 and the progression or regression of non-alcoholic fatty liver disease.
    Kawanaka M; Nishino K; Nakamura J; Urata N; Oka T; Goto D; Suehiro M; Kawamoto H; Yamada G
    Ann Hepatol; 2015; 14(6):837-44. PubMed ID: 26436355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels.
    Tsutsui M; Tanaka N; Kawakubo M; Sheena Y; Horiuchi A; Komatsu M; Nagaya T; Joshita S; Umemura T; Ichijo T; Matsumoto A; Yoshizawa K; Aoyama T; Tanaka E; Sano K
    J Clin Gastroenterol; 2010 Jul; 44(6):440-7. PubMed ID: 20104187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
    Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
    PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
    Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
    BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.